The medial preoptic nucleus integrates the central influences of testosterone on the paraventricular nucleus of the hypothalamus and its extended circuitries.
Testosterone contributes to sex differences in hypothalamic-pituitary-adrenal (HPA) function in humans and rodents, but the central organization of this regulation remains unclear. The medial preoptic nucleus (MPN) stands out as an important candidate in this regard because it contains androgen receptors and projects to forebrain nuclei integrating cognitive-affective information and regulating HPA responses to homeostatic threat. These include the HPA effector neurons of the paraventricular nucleus (PVN) of the hypothalamus, medial amygdala, and lateral septum. To test the extent to which androgen receptors in the MPN engage these cell groups, we compared in adult male rats the effects of unilateral microimplants of testosterone and the androgen receptor antagonist hydroxyflutamide into the MPN on acute restraint induced activation and/or neuropeptide expression levels. The basic effects of these implants were lateralized to the sides of the nuclei ipsilateral to the implants. Testosterone, but not hydroxyflutamide implants, decreased stress-induced Fos and arginine vasopressin (AVP) heteronuclear RNA expression in the PVN, as well as Fos expression in the lateral septum. In unstressed animals, AVP mRNA expression in the PVN decreased and increased in response to testosterone and hydroxflutamide MPN implants, respectively. The differential influences of these implants on AVP mRNA expression were opposite in the medial amygdala. These results confirm a role for androgen receptors in the MPN to concurrently modulate neuropeptide expression and activational responses in the PVN and its extended circuitries. This suggests that the MPN is capable of bridging converging limbic influences to the HPA axis with changes in gonadal status.
Williamson
Martin
M
Neuroscience Program, Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Bingham
Brenda
B
Gray
Megan
M
Innala
Leyla
L
Viau
Victor
V
D000728:Androgens; D000818:Animals; D004343:Drug Implants; D007276:Injections, Intraventricular; D008297:Male; D009415:Nerve Net / Q000187:drug effects / Q000378:metabolism*; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects* / Q000502:physiology*; D011301:Preoptic Area / Q000187:drug effects* / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011944:Receptors, Androgen / Q000378:metabolism; D013739:Testosterone / Q000008:administration & dosage / Q000097:blood / Q000502:physiology*
D000728:Androgens; D004343:Drug Implants; D011944:Receptors, Androgen; D013739:Testosterone
Nat Rev Neurosci. 2009 Jun;10(6):459-66
19339973
J Comp Neurol. 2001 Aug 6;436(4):430-55
11447588
Endocrinology. 2003 Jul;144(7):3067-75
12810563
J Comp Neurol. 1986 Apr 15;246(3):312-42
3517086
Prog Brain Res. 2000;126:117-32
11105644
Psychoneuroendocrinology. 2006 Jun;31(5):642-52
16616815
J Neuroendocrinol. 2010 Feb;22(2):92-101
20002965
J Neuroendocrinol. 2001 May;13(5):442-52
11328455
J Comp Neurol. 2007 Aug 20;503(6):717-40
17570493
Cell Tissue Res. 1990 Jul;261(1):17-23
2383883
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Dec;29(8):1239-48
16214282
J Comp Neurol. 2007 Jan 20;500(3):557-73
17120292
J Comp Neurol. 1993 Jun 1;332(1):123-43
7685780
Endocrinology. 2004 Jan;145(1):59-70
14563697
J Comp Neurol. 2006 Dec 20;499(6):911-23
17072840
J Neurosci. 1999 Aug 1;19(15):6684-93
10414997
Prog Brain Res. 1998;119:3-20
10074777
Neuroscience. 2006;138(3):947-55
16310321
Neurosci Lett. 1996 Oct 18;217(2-3):101-4
8916082
J Neuroendocrinol. 1994 Aug;6(4):433-42
7987374
Eur J Neurosci. 2005 Oct;22(7):1679-90
16197508
Brain Res. 1978 May 12;146(2):325-40
647393
J Neuroendocrinol. 1995 Nov;7(11):827-31
8748118
Eur J Neurosci. 1999 Jul;11(7):2312-22
10383620
Am J Physiol Regul Integr Comp Physiol. 2008 Oct;295(4):R1020-30
18685071
J Comp Neurol. 1988 Apr 8;270(2):209-42
3259955
Endocrinology. 2005 Jan;146(1):137-46
15375029
Endocrinology. 1987 Jul;121(1):233-40
3496208
Front Neuroendocrinol. 2004 Sep-Dec;25(3-4):150-76
15589267
J Comp Neurol. 1986 Apr 15;246(3):343-63
2422228
Brain Res Bull. 1985 Mar;14(3):261-72
3995367
Mol Endocrinol. 1991 Oct;5(10):1447-56
1775130
J Neurosci. 1996 Jan;16(1):262-73
8613792
J Comp Neurol. 1997 Dec 1;388(4):507-25
9388012
Biol Psychol. 2005 Apr;69(1):113-32
15740829
J Neurosci. 1993 Dec;13(12):5126-38
8254363
Front Neuroendocrinol. 1994 Dec;15(4):321-50
7895891
J Comp Neurol. 1980 Dec 1;194(3):555-70
7451682
J Comp Neurol. 2006 Jan 1;494(1):142-78
16304685
Ann N Y Acad Sci. 1994 Nov 14;743:95-120
7802421
Brain Res Brain Res Rev. 2001 Dec;38(1-2):192-246
11750933
J Comp Neurol. 2002 May 20;447(1):1-7
11967890
J Comp Neurol. 1998 Apr 6;393(2):244-66
9548700
J Neurosci. 2002 Feb 1;22(3):959-69
11826124
J Comp Neurol. 2004 Jan 6;468(2):277-98
14648685
Brain Res Brain Res Rev. 1997 Sep 19;24(2-3):115-95
9385454
Mol Endocrinol. 1992 Jul;6(7):1061-9
1324419
J Neurosci. 2007 Feb 21;27(8):2025-34
17314298
J Comp Neurol. 1995 Sep 18;360(2):213-45
8522644
J Neurosci. 2006 Feb 1;26(5):1448-56
16452668
J Comp Neurol. 1990 Apr 1;294(1):76-95
2324335
Brain Res. 1985 Jan 28;325(1-2):391-4
3978433
J Comp Neurol. 2002 Apr 15;445(4):293-307
11920708